Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age

Exclusion Criteria

• •1. Clinically significant new illness in the 1 month before screening and any time prior to randomization
• •2. Significant renal or hepatic disease
• •3. Secondary (chromosomal, endocrine, or metabolic) causes of obesity
• •4. Use of medications other than hormonal contraceptives and acetaminophen
• •5. Use of drugs with serotonergic activity within 1 month before screening
• •6. Recent treatment with over-the-counter weight loss products or appetite suppressants, or within 3 months of screening and any time prior to randomization with a prescription weight loss drug or lipid dissolving injections or ongoing psychotherapy for weight loss outside of this trial
• •7. Recent history of alcohol, tobacco, or recreational drug/solvent use
• •8. Any history of major depression, anxiety, bipolar disorder, schizophrenia, or Axis II psychiatric disease requiring treatment with prescription medication within six months prior to screening